Zolmitriptan

Zolmitriptan is an oral, selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist, or triptan, for acute treatment of migraine attacks with or without aura. First launched in 1997, it is one of the second generation of triptan. It is available in tablet form, as a rapidly dissolving tablet that can be taken without water, and as a nasal spray.

Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Greece & Argentina) and AscoTop (Germany).